A recent study demonstrated production of IL-15 by leukemia cells in patients with FLT3 mutations treated with Sorafenib, a tyrosine kinsase inhibitor which targets mutant FLT3, similar to Midostaurin (159, 160). This evidence concerns the gene FLT3 and leukemia.